Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

Abstract:

:Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In relation to the lipodystrophy syndrome, it appears that the most powerful determinant of subcutaneous fat wasting is an interaction between these two drug classes. In this review, possible mechanisms underlying the contributions of both PI and NRTI drugs are reviewed, with an emphasis on their effects on adipose tissue. On this basis, an 'adipocentric', or minimal model of the syndrome is developed, in which divergent effects at the adipocyte of NRTIs (mitochondrial toxicity) and PIs (insulin resistance and impaired adipocyte maturation) interact to produce a phenotype that is consistent with clinical observations.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Nolan D,John M,Mallal S

subject

Has Abstract

pub_date

2001-09-01 00:00:00

pages

145-60

issue

3

eissn

1359-6535

issn

2040-2058

journal_volume

6

pub_type

杂志文章,评审
  • Effect of long-term lamivudine in chronic hepatitis B virus-infected children.

    abstract:OBJECTIVE:To evaluate, retrospectively, biochemical, serological and histological responses in chronic hepatitis B (CHB)-infected children who received combination therapy and continued with prolonged treatment with lamivudine (3TC). PATIENTS AND METHODS:CHB infection was defined as the presence of hepatitis B surface...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Ozgenç F,Arikan C,Sertoz RY,Nart D,Aydogdu S,Yagci RV

    更新日期:2004-10-01 00:00:00

  • Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz (EFV) to RPV are limited. This study investigated the ph...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP3198

    authors: Jantarabenjakul W,Anugulruengkitt S,Kasipong N,Thammajaruk N,Sophonphan J,Bunupuradah T,Cressey TR,Colbers A,Burger DM,Phongsamart W,Puthanakit T,Pancharoen C,HIVNAT 220 study.

    更新日期:2018-01-01 00:00:00

  • P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

    abstract:BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1399

    authors: Janneh O,Anwar T,Jungbauer C,Kopp S,Khoo SH,Back DJ,Chiba P

    更新日期:2009-01-01 00:00:00

  • Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.

    abstract:BACKGROUND:Regulatory T-cells (Treg) hamper immune responses elicited by cancer vaccines. Therefore, depletion of Treg is being used to improve the outcome of vaccinations. METHODS:We studied whether an alphavirus vector-based immunotherapeutic vaccine changes the number and/or activity of Treg and if Treg depletion i...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1751

    authors: Walczak M,Regts J,van Oosterhout AJ,Boon L,Wilschut J,Nijman HW,Daemen T

    更新日期:2011-01-01 00:00:00

  • Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.

    abstract:BACKGROUND:We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir. METHODS:This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) al...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP1506

    authors: Dingemanse J,van Giersbergen PL,Patat A,Nilsson PN

    更新日期:2010-01-01 00:00:00

  • Prevalence of transmitted HIV-1 drug resistance among young adults attending HIV counselling and testing clinics in Kigali, Rwanda.

    abstract:BACKGROUND:Scaling-up antiretroviral therapy (ART) in resource-limited settings has raised concerns of emerging HIV drug resistance (DR) and its transmission to newly infected individuals. To assess the prevalence of transmitted drug resistance (TDR) in recently HIV-infected individuals, a WHO TDR threshold survey was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2999

    authors: Mutagoma M,Ndahimana Jd,Kayirangwa E,Dahourou AG,Balisanga H,DeVos JR,McAlister D,Yang C,Bertagnolio S,Riedel DJ,Nsanzimana S

    更新日期:2016-01-01 00:00:00

  • The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

    abstract:BACKGROUND:The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir. OBJECTIVE:To inve...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kruse G,Esser S,Stocker H,Breske A,Koerber A,Kopperman M,Wiehler H,Ross B,Möcklinghoff C,Hill A,Becker M,Kurowski M

    更新日期:2005-01-01 00:00:00

  • Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients.

    abstract:BACKGROUND:It remains unclear whether depression in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during pegylated interferon-based therapy is associated with the virus, drug or ethnic background. We aimed to perform a prospective study to evaluate the clinical course of depression and its predictors in conse...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2441

    authors: Huang YW,Hu JT,Hu FC,Chang CJ,Chang HY,Kao JH,Yang SS,Chen DS

    更新日期:2013-01-01 00:00:00

  • Drug-drug interactions in HIV therapy: is it all clear?

    abstract::Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2688

    authors: Burger D,Back D

    更新日期:2013-01-01 00:00:00

  • Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.

    abstract:BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3028

    authors: Drouot E,Piret J,Boivin G

    更新日期:2016-01-01 00:00:00

  • CD4(+) T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis.

    abstract:BACKGROUND:CD4(+) T-cell count recovery after antiretroviral therapy (ART) initiation is associated with improved health outcomes. It is unknown how the CD4(+) T-cell counts of African HIV patients recover following ART initiation. METHODS:We examined CD4(+) T-cell count recovery in a large cohort of HIV-positive pati...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2670

    authors: Kanters S,Nachega J,Funk A,Mukasa B,Montaner JS,Ford N,Bucher HC,Mills EJ

    更新日期:2014-01-01 00:00:00

  • Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

    abstract:BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2671

    authors: Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

    更新日期:2013-01-01 00:00:00

  • Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

    abstract:BACKGROUND:Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (NAMs) can affect response to treatment with NRTIs and might also result in HIV-1 with reduced replication capacity. METHODS:A large commercial HIV-1 database (n=60,487) was analysed for the prevalence of NAMs, antiviral drug susceptibil...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: McColl DJ,Chappey C,Parkin NT,Miller MD

    更新日期:2008-01-01 00:00:00

  • Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

    abstract:BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3372

    authors: Jia J,Shang J,Tang H,Jiang J,Ning Q,Dou X,Zhang S,Zhang M,Han T,Tan D,Zhou X,Chen G,Sheng J,Su Z,Chen H,Dai E,Ye Y,Guo Y,Shen Y,Yuan J,Wei Z,Zhu S,EVOLVE Study Group.

    更新日期:2020-10-22 00:00:00

  • Sodium tanshinone IIA sulfonate inhibits porcine reproductive and respiratory syndrome virus via suppressing N gene expression and blocking virus-induced apoptosis.

    abstract:BACKGROUND:Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant economic loss in the swine industry. Currently, there is no effective way to prevent PRRSV infection. Sodium tanshinone IIA sulfonate (STS), a natural compound derived from Salvia miltiorrhiza, was shown to possess anti-PRRSV acti...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2694

    authors: Sun N,Li E,Wang Z,Zhao J,Wang S,He J,Bai Y,Li H

    更新日期:2014-01-01 00:00:00

  • Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

    abstract:OBJECTIVE:To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed. METHODS:The Narval trial was designed to compare phenotyping, genotyping and standard of care for the choice of antiretroviral therapy in patients in whom a protease inhibitor (PI)-con...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Vray M,Meynard JL,Dalban C,Morand-Joubert L,Clavel F,Brun-Vézinet F,Peytavin G,Costagliola D,Girard PM,Narval Trial Group.

    更新日期:2003-10-01 00:00:00

  • Viral hepatitis and HIV: update and management.

    abstract::HCV-related liver disease is an important contributor to morbidity and mortality in the HIV-infected population. Successful treatment of HIV-HCV-coinfected patients is followed by favourable clinical outcomes. While the combination of pegylated interferon and ribavirin remains the mainstay in the treatment of non-1 HC...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2601

    authors: Núñez M,Mendes-Correa MC

    更新日期:2013-01-01 00:00:00

  • Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.

    abstract:BACKGROUND:Pegylated interferon/ribavirin combination is currently the standard treatment for chronic hepatitis C virus (HCV) infection. Body weight adjustment of ribavirin is crucial for response. However, previous studies found no relation between ingested dose and plasma concentration. The aim of this study was to d...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Maynard M,Pradat P,Gagnieu MC,Souvignet C,Trepo C

    更新日期:2008-01-01 00:00:00

  • Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

    abstract::Infection with influenza viruses, including seasonal, avian and pandemic viruses, remains a worldwide public health problem. Although influenza virus infection is both vaccine preventable and drug treatable, high rates of mutation and reassortment of viruses can result in reduced effectiveness of vaccines or drugs. Cu...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2067

    authors: Nguyen HT,Fry AM,Gubareva LV

    更新日期:2012-01-01 00:00:00

  • Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

    abstract:BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3137

    authors: Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

    更新日期:2017-01-01 00:00:00

  • Management of hepatitis B patients with antiviral resistance.

    abstract::Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Fung SK,Lok AS

    更新日期:2004-12-01 00:00:00

  • Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-

    abstract:BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3851/IMP1532

    authors: Paediatric European Network for Treatment of AIDS (PENTA).

    更新日期:2010-01-01 00:00:00

  • HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

    abstract::Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2425

    authors: Calle Serrano B,Manns MP

    更新日期:2012-01-01 00:00:00

  • Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.

    abstract:BACKGROUND:Ageing HIV-infected patients present an increased incidence of cardiovascular diseases, endothelial dysfunction being an early alteration. Some protease inhibitors (PIs) have been shown to increase the risk of cardiovascular disease. We evaluated here the effects of CCR5 or integrase inhibitors as compared t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3160

    authors: Afonso P,Auclair M,Caron-Debarle M,Capeau J

    更新日期:2017-01-01 00:00:00

  • Ribavirin considerations in treatment optimization.

    abstract::Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Dusheiko G,Nelson D,Reddy KR

    更新日期:2008-01-01 00:00:00

  • Evolution of renal function in African patients initiating second-line antiretroviral treatment: findings from the ANRS 12169 2LADY trial.

    abstract:BACKGROUND:To investigate change in renal function in African patients initiating second-line antiretroviral therapy (ART) including ritonavir-boosted protease inhibitor (PI/r) with or without tenofovir disoproxil fumarate (TDF). METHODS:HIV-1-positive adults, failing standard first-line ART were randomized to either ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3097

    authors: Cournil A,Hema A,Eymard-Duvernay S,Ciaffi L,Badiou S,Kabore FN,Diouf A,Ayangma L,Le Moing V,Reynes J,Koulla-Shiro S,Delaporte E,2LADY Study Group.

    更新日期:2017-01-01 00:00:00

  • Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

    abstract:BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Duraffour S,Snoeck R,de Vos R,van Den Oord JJ,Crance JM,Garin D,Hruby DE,Jordan R,De Clercq E,Andrei G

    更新日期:2007-01-01 00:00:00

  • Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients.

    abstract::With the recent approval of several drugs for the management of chronic hepatitis B, the proper diagnosis and classification of this disease is necessary to determine if therapy is needed and what the best treatment options are. The diagnosis of chronic hepatitis B relies on serological testing, and disease stage is f...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Thio CL

    更新日期:2007-01-01 00:00:00

  • Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

    abstract:BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

    更新日期:2008-01-01 00:00:00

  • Altered heterochromatin organization after perinatal exposure to zidovudine.

    abstract:BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Senda S,Blanche S,Costagliola D,Cibert C,Nigon F,Firtion G,Floch C,Parat S,Viegas-Péquignot E

    更新日期:2007-01-01 00:00:00